GABA_A receptor subtype modulators in medicinal chemistry: an updated patent review (2014-present)

References

• Chua HC, Chebib M. Chapter one – GABAA receptors and the diversity in their structure and pharmacology. Adv Pharmacol. 2017;79:1–34.
   PubMedGoogle Scholar
• Yamasaki T, Hoyos-Ramirez E, Martenson JS, et al. GARLH family proteins stabilize GABAA receptors at synapses. Neuron. 2017;93(5):1138–1152.e6.
   PubMed Web of Science ®Google Scholar
• Tomita S. Molecular constituents and localization of the ionotropic GABA receptor complex in vivo. Curr Opin Neurobiol. 2019;57:81–86. .
   PubMed Web of Science ®Google Scholar
• Olsen RW, Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009;56(1):141–148.
   PubMed Web of Science ®Google Scholar
• Baumann SW, Baur R, Sigel E. Forced subunit assembly in α1β2γ2 GABAA receptors: insight into the absolute arrangement. J Biol Chem. 2002;277(48):46020–46025.
   PubMed Web of Science ®Google Scholar
• Sieghart W. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Adv Pharmacol. 2015;72:53–96.
   PubMedGoogle Scholar
• Solomon VR, Tallapragada VJ, Chebib M, et al. GABA allosteric modulators: an overview of recent developments in non-benzodiazepine modulators. Eur J Med Chem. 2019;171:434–461 .
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Lester HA, Lummis SCR. The structural basis of function in Cys-loop receptors. Q Rev Biophys. 2010;43(4):449–499.
   PubMed Web of Science ®Google Scholar
• Sigel E, Ernst M. The benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Sci. 2018;39(7):659–671.
   PubMed Web of Science ®Google Scholar
• Crestani F, Rudolph U. Behavioral functions of GABAA receptor subtypes - The zurich experience. Adv Pharmacol. 2015;72:37–51.
   PubMedGoogle Scholar
• Ramerstorfer J, Furtmüller R, Sarto-Jackson I, et al. The GABAA receptor alpha+beta- interface: a novel target for subtype selective drugs. J Neurosci. 2011;31(3):870–877.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Ramerstorfer J, Sarto-Jackson I, et al. A novel GABAA receptor pharmacology: drugs interacting with the α+β- interface. Br J Pharmacol. 2012;166(2):476–485.
   PubMed Web of Science ®Google Scholar
• Varagic Z, Wimmer L, Schnürch M, et al. Identification of novel positive allosteric modulators and null modulators at the GABAA receptor α+β- interface. Br J Pharmacol. 2013;169(2):371–383.
   PubMed Web of Science ®Google Scholar
• Vasović D, Divović B, Treven M, et al. Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABA A receptors. Eur J Pain. 2019;23(5):973–984.
   PubMed Web of Science ®Google Scholar
• Chiou L-C, Lee H-J, Ernst M, et al. Cerebellar α 6 -subunit-containing GABA A receptors: a novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders. Br J Pharmacol. 2018;175(12):2414–2427.
   PubMed Web of Science ®Google Scholar
• Varagic Z, Ramerstorfer J, Huang S, et al. Subtype selectivity of α+β- site ligands of GABAA receptors: identification of the first highly specific positive modulators at α6β2/3γ2 receptors. Br J Pharmacol. 2013;169(2):384–399.
   PubMed Web of Science ®Google Scholar
• Treven M, Siebert DCB, Holzinger R, et al. Towards functional selectivity for α6β3γ2 GABAA receptors: a series of novel pyrazoloquinolinones. Br J Pharmacol. 2018;175(3):419–428.
   PubMed Web of Science ®Google Scholar
• Knutson DE, Kodali R, Divović B, et al. Design and synthesis of novel deuterated ligands functionally selective for the γ-aminobutyric acid type a receptor (GABA A R) α6 subtype with improved metabolic stability and enhanced bioavailability. J Med Chem. 2018;61(6):2422–2446.
   PubMed Web of Science ®Google Scholar
• Walters RJ, Hadley SH, Morris KD, et al. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat Neurosci. 2000;3(12):1274–1281.
   PubMed Web of Science ®Google Scholar
• Middendorp SJ, Maldifassi MC, Baur R, et al. Positive modulation of synaptic and extrasynaptic GABAA receptors by an antagonist of the high affinity benzodiazepine binding site. Neuropharmacology. 2015;95:459–467.
   PubMed Web of Science ®Google Scholar
• Brejc K, van Dijk WJ, Klaassen RV, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature. 2001;411(6835):269–276.
   PubMed Web of Science ®Google Scholar
• Zhang W, Koelher K, Zhang P, et al. Development of a comprehensive pharmacophore model for the benzodiazepine receptor. Drug Des Discovery. 1995;12(3):193–248.
   PubMedGoogle Scholar
• Zhu S, Noviello CM, Teng J, et al. Structure of a human synaptic GABAA receptor. Nature. 2018;559(7712):67–88.
   PubMed Web of Science ®Google Scholar
• Phulera S, Zhu H, Yu J, et al. Cryo-EM structure of the benzodiazepine-sensitive α1β1γ2S tri-heteromeric GABA A receptor in complex with GABA. Elife. 2018;7:1–21.
   Web of Science ®Google Scholar
• Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012;287(48):40224–40231.
   PubMed Web of Science ®Google Scholar
• Scott S, Aricescu AR. A structural perspective on GABAA receptor pharmacology. Curr Opin Struct Biol. 2019;54:189–197.
   PubMed Web of Science ®Google Scholar
• Masiulis S, Desai R, Uchański T, et al. GABAA receptor signalling mechanisms revealed by structural pharmacology. Nature. 2019;565(7740):454–459 .
   PubMed Web of Science ®Google Scholar
• Amundarain MJ, Ribeiro RP, Costabel M, et al. GABAA receptor family: overview on structural characterization. Future Med Chem. 2019;11(3):229–245. .
   Web of Science ®Google Scholar
• Engin E, Benham RS, Rudolph U. An emerging circuit pharmacology of GABAA receptors. Trends Pharmacol Sci. 2018;39(8):710–732.
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU, Ralvenius WT, Acuña MA. Restoring the spinal pain gate: GABAA receptors as targets for novel analgesics. Adv Pharmacol. 2015;73:71–96.
   PubMedGoogle Scholar
• Sieghart W, Savić MM. International union of basic and clinical pharmacology. CVI: GABAA receptor subtype- and function-selective ligands: key issues in translation to humans. Pharmacol Rev. 2018;70(4):836–878.
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010;24(11):1601–1612.
   PubMed Web of Science ®Google Scholar
• Xu M, Wong AHC. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. Acta Pharmacol Sin. 2018;39(5):733–753.
   PubMed Web of Science ®Google Scholar
• Prevot TD, Li G, Vidojevic A, et al. Novel benzodiazepine-like ligands with various anxiolytic, antidepressant, or pro-cognitive profiles. Mol Neuropsychiatry. 2019;5(2):84–97.
   PubMedGoogle Scholar
• Braat S, Kooy RF. The GABA A receptor as a therapeutic target for neurodevelopmental disorders. Neuron. 2015;86(5):1119–1130.
   PubMed Web of Science ®Google Scholar
• Jacob TC, Olsen RW, Sieghart W. Neurobiology and therapeutic potential of α5-GABA type a receptors. Front Mol Neurosci. 2019;12:1–10.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun H, Chen Z, et al. Implications of GABAergic neurotransmission in alzheimer’s disease. Front Aging Neurosci. 2016;8:31.
   PubMed Web of Science ®Google Scholar
• Möhler H, Rudolph U. Disinhibition, an emerging pharmacology of learning and memory. F1000Res. 2017;6:1–11.
   Google Scholar
• Mizuta K, Xu D, Pan Y, et al. GABAA receptors are expressed and facilitate relaxation in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2008;294(6):L1206–16.
   PubMed Web of Science ®Google Scholar
• Forkuo GS, Guthrie ML, Yuan NY, et al. Development of GABAA receptor subtype-selective imidazobenzodiazepines as novel asthma treatments. Mol Pharm. 2016;13(6):2026–2038 .
   PubMedGoogle Scholar
• Gallos G, Yocum GT, Siviski ME, et al. Selective targeting of the α5-subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handling. Am J Physiol Lung Cell Mol Physiol. 2015;308(9):L931–L942. .
   PubMed Web of Science ®Google Scholar
• Forkuo GS, Nieman AN, Yuan NY, et al. Alleviation of multiple asthmatic pathologic features with orally available and subtype selective GABAA receptor modulators. Mol Pharm. 2017;14:2088–2098.
   PubMedGoogle Scholar
• Zahn NM, Huber AT, Mikulsky BN, et al. MIDD0301 – A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression. Basic Clin Pharmacol Toxicol. 2019;125(1):75–84.
   PubMed Web of Science ®Google Scholar
• Green MV, Thayer SA. HIV gp120 upregulates tonic inhibition through α5-containing GABA A Rs. Neuropharmacology. 2019;149:161–168.
   PubMed Web of Science ®Google Scholar
• Kallay L, Keskin H, Ross A, et al. Modulating native GABA A receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death. J Neurooncol. 2019;142(3):411–422.
   PubMed Web of Science ®Google Scholar
• Astrazeneca AB. Substituted cinnoline derivatives as GABAA-receptor modulators and method for their synthesis. WO2007073283A1. 2007.
   Google Scholar
• Clinicaltrials.gov NCT03140813. An initial study of AZD7325 in adults with fragile X syndrome - full text view - clinicaltrials.gov. NCT03140813. 2018.
   Google Scholar
• Telias M. Molecular mechanisms of synaptic dysregulation in fragile X syndrome and autism spectrum disorders. Front Mol Neurosci. 2019;12:51.
   PubMed Web of Science ®Google Scholar
• D’Hulst C, Heulens I, Van der Aa N, et al. Positron Emission Tomography (PET) quantification of GABAA receptors in the brain of fragile X patients. Bardoni B, editor. PLoS One. 2015;10(7):e0131486.
   PubMed Web of Science ®Google Scholar
• Nomura T, Hawkins N, Kearney J, et al. Potentiating α 2 subunit containing perisomatic GABA A receptors protects against seizures in a mouse model of Dravet syndrome. J Physiol. 2019;597(16):4293–4307.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov NCT03678129. GABA Pathways in Autism Spectrum Disorder (ASD) - full text view - clinicaltrials.gov. NCT03678129. 2019.
   Google Scholar
• Pfizer Limited. Imidazopyridazine derivatives as GABAA receptor modulators. 2014. WO2014/091368A1.
   Google Scholar
• Clinicaltrials.gov NCT02564029. PF-06372865 in subjects with photosensitive epilepsy - full text view - clinicalTrials.gov. NCT02564029. 2017.
   Google Scholar
• Clinicaltrials.gov NCT02262754. PF-06372865 In subjects with chronic low back pain - full text view - clinicaltrials.gov. NCT02262754. 2017.
   Google Scholar
• Gurrell R, Gorman D, Whitlock M, et al. Photosensitive epilepsy: robust clinical efficacy of a selective GABA potentiator. Neurology. 2019;92(15):e1786–e1795.
   PubMed Web of Science ®Google Scholar
• Owen RM, Blakemore DC, Cao L, et al. Design and identification of a novel, functionally subtype selective GABAA positive allosteric modulator (PF-06372865). J Med Chem. 2019;62(12):5773–5796.
   PubMed Web of Science ®Google Scholar
• Van Amerongen G, Siebenga PS, Gurrell R, et al. Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans. Br J Anaesth. 2019;123(2):e194–e203.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche Inc. Isoxazolo-pyridine derivatives. WO2009/071476A1. 2009.
   Google Scholar
• Bolognani F, Squassante L, Liogier d’Ardhuy X, et al. RG1662, a selective GABAA α5 receptor negative allosteric modulator, increases gamma power in young adults with down syndrome. (P6.273). Neurology. 2015;84.
   Google Scholar
• Clinicaltrials.gov NCT02024789. A study of RG1662 in adults and adolescents with down syndrome (CLEMATIS) - full text view - clinicalTrials.gov. NCT02024789. 2017.
   Google Scholar
• Clinicaltrials.gov NCT02953639. A study to evaluate the effects of basmisanil in participants with Cognitive Impairment Associated With Schizophrenia (CIAS) treated with antipsychotics - full text view - clinicaltrials.gov. NCT02953639. 2019.
   Google Scholar
• Les Laboratoires Servier, Egis Gyogyszerguar Nyrt. Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them. US8778932 B2. 2014.
   Google Scholar
• Clinicaltrials.gov NCT02877615. Efficacy and safety trial with s 44819 after recent ischemic cerebral event - full text view - clinicalTrials.gov. NCT02877615. 2019.
   Google Scholar
• Darmani G, Zipser CM, Böhmer GM, et al. Effects of the selective α5-GABAAR antagonist S44819 on excitability in the human brain: A TMS–EMG and TMS–EEG phase I study. J Neurosci. 2016;36(49):12312–12320.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov NCT03635437. Evaluation of safety and diabetes status upon oral treatment with GABA in patients with longstanding type-1 diabetes - full text view - clinicaltrials.gov. NCT03635437. 2019.
   Google Scholar
• Children’s Hospital Medical center. Compositions and methods for treatments of Fragile X syndrome. US2019/0083493A1. 2019.
   Google Scholar
• Children’s Hospital Medical center. Compositions and methods for treatment of Fragile X syndrome. US9844551B2. 2017.
   Google Scholar
• Children’s Hospital Medical center. Compositions and methods for treatment of Fragile X syndrome. US10159673B2. 2018.
   Google Scholar
• Hoffmann-La Roche Inc. Use of selective GABAA alpha5 negative allosteric modulators for the treatment of central nervous system conditions. US2019/0270734 A1. 2019.
   Google Scholar
• Hoffmann-La Roche Inc. Solid forms. US8975397B2. 2015.
   Google Scholar
• Jensen HS, Nichol K, Lee D, et al. Clobazam and its active metabolite n-desmethylclobazam display significantly greater affinities for α2- versus α1-gabaa–receptor complexes. Rudolph U, editor. PLoS One. 2014;9(2):e88456.
   PubMed Web of Science ®Google Scholar
• Les Hopitaux Universitaires de Geneve, Universitat Zurich, Universite de Geneve. Use of N-desmethylclobazam in the treatment of chronic pain disorders and related methods. EP3265095B1. 2019.
   Google Scholar
• The Regents of the University of California. Mitigation of epileptic seizure by combination therapy using benzodiazepines and neurosteroids. US10426786 B2. 2019.
   Google Scholar
• The Regents of the University of California. Enhancing Beta cell replication and/or survival. WO2017/066240 A1. 2017.
   Google Scholar
• The Regents of the University of California. Enhancing GABA’s ability to modulate immune responses. WO2018/236955A1. 2018.
   Google Scholar
• Braun M, Ramracheya R, Bengtsson M, et al. Gamma-aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic beta-cells. Diabetes. 2010;59:1694–1701. Available from http://www.ncbi.nlm.nih.gov/pubmed/20413510
   PubMed Web of Science ®Google Scholar
• Lustman PJ, Griffith LS, Clouse RE, et al. Effects of alprazolam on glucose regulation in diabetes. Results of double-blind, placebo-controlled trial. Diabetes Care. 1995;18(8):1133–1139. Available from.
   PubMed Web of Science ®Google Scholar
• Labance SE. Treatment of autism spectrum disorders (ASD). US2018/0055827A1. 2018.
   Google Scholar
• University of Maryland - Baltimore. Use of negative modulators of GABAA receptor containing alpha5 subunits as fast acting antidepressats. US2017/0020892A1. 2017.
   Google Scholar
• University of Washington Through its Center for Commercialization. Positive allosteric modulators of the GABA-A receptor in the treatment of autism. US2015/0313913A1. 2015.
   Google Scholar
• Universitat Zurich. Use of GABAA receptor modulators for the treatment of itch. US2019/0134057A1. 2019.
   Google Scholar
• Guerrini G, Ciciani G. Benzodiazepine receptor ligands: a patent review (2006-2012). Expert Opin Ther Pat. 2013;23(7):843–866.
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors. US8865719 B2. 2014.
   Google Scholar
• Centre National de La Recherche Scientifique -CNRS. Composition and method for treating cognitive impairments in down syndrom subjects. US9078874 B2. 2015.
   Google Scholar
• AgeneBio Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment. US9145372B2. 2015.
   Google Scholar
• Concert Pharmaceuticals Inc. Dosage regime for GABAA receptor subtype selective drug. WO2015/095549A1. 2015.
   Google Scholar
• Concert Pharmaceuticals Inc. Substituted triazolo-pyridazine derivatives. AU2014202485A1. 2014.
   Google Scholar
• Concert Pharmaceuticals Inc. Substituted triazolo-pyridazine derivatives. US2015/0111895A1. 2015.
   Google Scholar
• University of Maryland - Baltimore. Novel Gamma aminobutyric acid type A receptor modulators for mood disorders. WO2019/046300A1. 2019.
   Google Scholar
• AgeneBio Inc. Methods and compositions for treating schizofrenia. WO2014/078377 A1. 2014.
   Google Scholar
• Aniona APS. A phenyl triazole derivative and its use for modulating the GABAA receptor complex. WO2014/001278 A1. 2014.
   Google Scholar
• Aniona APS. A phenyl triazole derivative and its use for modulating the GABAA receptor complex. 2014 WO2014/001279 A1.
   Google Scholar
• Aniona APS. A phenyl triazole derivative and its use for modulating the GABAA receptor complex. 2014 WO2014/001280 A1.
   Google Scholar
• Saniona A/S. Phenyl triazole derivative and its use for modulating the GABAA receptor complex. US 9931329 B2. 2018.
   Google Scholar
• Saniona A/S. Phenyl triazole derivative and its use for modulating the GABAA receptor complex. US 9884848 B2. 2018.
   Google Scholar
• Hoffmann-La Roche Inc. New isoxazolyl ether derivatives as GABAA alpha5 PAM. WO2018/104419 A1. 2018.
   Google Scholar
• ONO Pharmaceutical CO. LTD. Fused imidazole compounds. US10016439 B2. 2018.
   Google Scholar
• Pfizer Limited. 4-(Biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain. WO2017/098367A1. 2017.
   Google Scholar
• Pfizer Limited. Imidazopyridazine derivatives as modulators of the GABAA receptor activity. WO2015/189744A1. 2015.
   Google Scholar
• AgeneBio Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. US2018/0170941 A1. 2018.
   Google Scholar
• AgeneBio Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. US2019/0055258 A1. 2019.
   Google Scholar
• AgeneBio Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. 2019 US10329301 B2.
   Google Scholar
• Achermann G, Ballard TM, Blasco F, et al. Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABAA α5 inverse agonist series. Bioorg Med Chem Lett. 2009;19(19):5746–5752.
   PubMed Web of Science ®Google Scholar
• Chambers MS, Atack JR, Broughton HB, et al. Identification of a novel, selective GABAA α5 receptor inverse agonist which enhances cognition. 2003;46:2227-2240 .
   Google Scholar
• Egis Gyogyszerguar Zrt. Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them. US9926332 B2. 2018.
   Google Scholar
• Innovationspatent Sverige AB. GABAA Receptor modulators. US8809355B2. 2014.
   Google Scholar
• The Johns Hopkins University, Lieber Institute Inc. Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other aliments of the peripheral nervous system. US2017/0197967A1. 2017.
   Google Scholar
• UWM Research Foundation Inc. Gabaergic ligands and their uses. US10259815 B2. 2019.
   Google Scholar
• UWM Research Foundation Inc., The Research Foundation for the State University of New York. Novel combination therapy for anxiety disorders, epilepsy, and pain. WO2019/070910A1. 2019.
   Google Scholar
• Cook JM, Van Linn M, Wenyuan Y. Aza-beta-carbolines and methods of using same. 2009/US2009306121 A1. 2009.
   Google Scholar
• Lewter LA, Fisher JL, Siemian JN, et al. Antinociceptive effects of a novel α2/α3-subtype selective GABAA receptor positive allosteric modulator. ACS Chem Neurosci. 2017;8(6):1305–1312.
   PubMed Web of Science ®Google Scholar
• UWM Research Foundation Inc. Gabaergic receptor subtype selective ligands and their uses. US9597342B2. 2017.
   Google Scholar
• UWM Research Foundation Inc., Centre for addiction and mental health, University of Belgrade - Faculty of Pharmacy. Treatment od cognitive and mood symptoms in neurodegenerative and neuropsychiaric disorder with alpha-5containing GABAA receptor agonists. WO2017/161370A1. 2017.
   Google Scholar
• Jahan R, Stephen MR, Forkuo GS, et al. Optimization of substituted imidazobenzodiazepines as novel asthma treatments. Eur J Med Chem. 2017;126:550–560.
   PubMed Web of Science ®Google Scholar
• UWM Research Foundation Inc., The Trustee of Columbia University in the City of New York. GABAA receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma. WO2018/035246A1. 2018.
   Google Scholar
• UWM Research Foundation Inc. Novel GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma. US2015/0232473A1. 2015.
   Google Scholar
• UWM Research Foundation Inc., Medical University of Vienna, National Taiwan University, et al. Ligands selective to alpha6 subunit-containing GABAA receptors and their methods of use. WO2016/196961 A1. 2016.
   Google Scholar
• Arnold LA, Forkuo GS, Nieman AN, et al. A new pharmacological approach for asthma through tissue-specific modulation of the GABA(A) receptor. J Allergy Clin Immunol. 2016;137(2):AB393.
   Web of Science ®Google Scholar
• Arnold L, Forkuo G, Nieman A, et al. New oral treatments for asthma through tissue-specific modulation of the GABAA receptor. J Allergy Clin Immunol. 2017;139(2):AB9.
   Web of Science ®Google Scholar
• Rudolph U, Crestani F, Mohler H. GABAA receptor sybtypes: dissecting their pharmacological functions. Trends Pharmacol Sci. 2001;22(4):188–194.
   PubMed Web of Science ®Google Scholar
• Skolnick P. Anxioselective anxiolytics: on a quest for the Holy Grail. Trends Pharmacol Sci. 2012;33(11):611–620.
   PubMed Web of Science ®Google Scholar
• Allergan Inc. Gabaa receptor antagonists affecting ganglion cell function and visula function. WO2015/009533 A1. 2015.
   Google Scholar